Vaxart Inc. – Material Contracts Watch

from S-1/A 13 pages Registration Rights Agreement

from S-1/A 36 pages Purchase Agreement

from 10-Q 2 pages Vaxart, Inc. Non-Employee Director Compensation Program

from 8-K 13 pages Registration Rights Agreement

from 8-K 36 pages Purchase Agreement

from 10-K 5 pages Certain Information in This Document, Marked by [***], Has Been Excluded Pursuant to Regulation S-K, Item 601(b)(10)(iv). Such Excluded Information Is Not Material and Is the Type That the Registrant Treats as Private or Confidential. Termination Agreement

from 10-Q 22 pages Securities Purchase Agreement

from 10-Q 83 pages Exclusive License and Collaboration Agreement Between Vaxart, Inc. and Dynavax Technologies Corporation Exclusive License and Collaboration Agreement

from 10-Q 3 pages Certain Information Contained in This Document, Marked by “[***]”, Has Been Omitted Because It Constitutes a Clearly Unwarranted Invasion of Personal Privacy

from 10-K 2 pages Description of Modification

from 8-K 18 pages Description of Modification

from 10-Q 2 pages Description of Modification

from 10-Q 25 pages Specific Terms in This Exhibit Have Been Redacted Because Such Terms Are Both Not Material and Are the Type That the Registrant Treats as Private or Confidential. These Redacted Terms Have Been Marked in This Exhibit With Three Asterisks as [***]. Rrpv Project Award Number: 001 Rrpv Project Title: Rrpv-24-04-Ngvx-003; Oral Mucosal Vaccine for Sars-Cov2 Protection Uei Number: Ws6umd1qtbc9 Parties: Advanced Technology International (Rrpv Consortium Management Firm or Cmf) and Vaxart Biosciences Inc (Project Awardee) 1. Payment Method the Payment Method for This Project Award Is Firm Fixed Price and Expenditure-Based With Fixed Fee Milestone With a Not to Exceed Ceiling. 2. Term of the Project Award the Period of Performance for This Project Award Is From the Effective Date, Which Is the Date of Last Signature, Through [***]. 3. Obligation the Cmf’s Liability to Make Payments to the Project Awardee Is Limited to Only Those Funds Obligated Under This Project Award or by Modification to the Project Award. the Cmf May Incrementally Fund This Project Award. 4. Project Agreement Ceiling the Total Estimated Ceiling for This Project Awardee Is $[***] Broken Out as Follows: Firm Fixed Price the Total Fixed Amount for the Services to Be Provided by the Project Awardee Are as Follows: Fixed Amount (Milestone 2 Only) $[***] Estimated Expenditure and Fixed Fee the Total Estimated Expenditure and Fixed Fee for the Services to Be Provided by the Project Awardee Are as Follows: Estimated Expenditure Estimated Expenditure $[***] Fixed Fee $[***] Total Cost $[***]

from 10-Q 43 pages Rrpv Base Agreement Between Advanced Technology International 315 Sigma Drive Summerville, Sc 29486 and Rrpv Member Organization Vaxart Biosciences Inc 170 Harbor Way Ste 300 South San Francisco, California 94080-6102 Uei: Ws6umd1qtbc9

from 10-Q 2 pages Vaxart, Inc. Non-Employee Director Compensation Program

from 8-K 18 pages Vaxart, Inc. 2022 Employee Stock Purchase Plan

from 8-K 20 pages Vaxart, Inc. 2019 Equity Incentive Plan Adopted by the Board of Directors: February 26, 2019 Approved by the Stockholders: April 23, 2019 1st Amendment Approved by the Stockholders: June 8, 2020 2nd Amendment Approved by the Stockholders: June 16, 2021 3rd Amendment Approved by the Stockholders: August 4, 2022 4th Amendment Approved by the Stockholders: June 11, 2024

from 10-K 77 pages Part I – The Schedule Section B – Supplies or Services and Prices/Costs B.1. Brief Description of Services

from 8-K 4 pages February 21, 2024 Steven Lo via Email Re: Offer of Employment Salary, Bonus Rate and Benefits

from 8-K 13 pages Vaxart, Inc. Stock Option Grant Notice